INFINITT earns high marks in 2022 Best in KLAS Report

Media Release February 24, 2022

 

KLAS Research, a healthcare IT market research firm, released its 2022 Best in KLAS report earlier this month, ranking more than 1,000 health informatics solutions installed across the US.

According to KLAS, the Best in KLAS report recognizes software and services companies who excel in helping healthcare professionals improve patient care. All rankings are a direct result of the feedback they’ve received from thousands of providers over the last year.

In the PACS product category for large healthcare facilities with more than 300,000 studies per year, INFINITT came in a close second to Sectra, with Sectra PACS scoring 88.5 and INFINITT PACS, 88.0. INFINITT PACS, however, was not fully ranked because KLAS did not obtain feedback from 15 unique organizations in the large hospital category.

In the Cardiology imaging market segment, INFINITT Cardiology Suite came in with the highest score at 87.1 based on 16 evaluations, while Fujifilm Synapse Cardiovascular took top ranking with a score of 83.6.

In the small hospital PACS market, classified as healthcare organizations with less than 300,000 studies per year, INFINITT PACS was ranked fourth with a score of 85.2. The 2022 Best in KLAS report also referenced their Imaging in the Cloud 2021 report, which stated “INFINITT stands out for helping organizations seamlessly transition their PACS production environment to the cloud, thanks to thorough implementations and strong client partnerships.”1

1 KLAS Research, Ltd.: Imaging in the Cloud 2021: Early Adoption Shows Promising Results, November 2021. All rights reserved.

About INFINITT North America INFINITT North America is the North American business unit of INFINITT Healthcare, a global company with more than 6500 installations in 55 countries. INFINITT's enterprise imaging solutions include INFINITT Healthcare Platform (VNA), RIS, PACS, Mammography PACS, Cardiology Suite, Digital Pathology PACS, RT PACS, Dental PACS, Ophthalmology PACS, an AI Platform and an Advanced Visualization software platform. For more information, call 877-387-6960, visit infinittna.com , or see us at HIMSS22, March 15-17, 2022, in Orlando, FL.

Around the web

The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.

GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.

Trimed Popup
Trimed Popup